ARIAD Pharmaceuticals (ARIA) announced that it has completed rolling submission of its New Drug Application (NDA) to the FDA seeking approval of Breakthrough Therapy- and Orphan Drug-tagged brigatinib for the treatment of patients with ALK+ non-small cell lung cancer (NSCLC) who are resistant to Pfizer's (PFE) XALKORI (crizotinib). The company has requested accelerated review of the filing.